Source comparison
Tesamorelin Ipamorelin Stack Visceral Fat Reduction Protocol 2026: Evidence Comparison
Tesamorelin monotherapy (2mg daily) 15–18% GHRH receptor agonism → pituitary GH secretion Injection site reactions (12%), transient hyperglycaemia (8%) Effective but limited by receptor desensitisation after 16–20 weeks. Response plateaus without cycling off I
This comparison does not assign a generated winner or score.
- Tesamorelin monotherapy (2mg daily)
- 15–18%
- GHRH receptor agonism → pituitary GH secretion
- Injection site reactions (12%), transient hyperglycaemia (8%)
- Effective but limited by receptor desensitisation after 16–20 weeks. Response plateaus without cycling off
- Ipamorelin monotherapy (300mcg daily)
- 8–11%
- Ghrelin receptor agonism → pulsatile GH release
- Minimal. Transient hunger immediately post-dose (15%)
- Insufficient as monotherapy for clinically meaningful VAT reduction. Best used in combination
- Tesamorelin + ipamorelin stack (2mg + 300mcg)
- 24–30%
- Dual pathway GH amplification (GHRH + ghrelin receptor)
- Similar to tesamorelin alone. No additive side effects observed
- Gold standard for VAT-specific fat loss. Synergistic effect far exceeds additive prediction
- CJC-1295 + ipamorelin
- 18–22%
- Long-acting GHRH analogue + ghrelin receptor agonism
- Injection site nodules (18%), prolonged GH elevation (may affect insulin sensitivity)
- Comparable efficacy but less favourable pharmacokinetics. CJC half-life of 6–8 days makes dose adjustments difficult
- Diet + exercise (caloric deficit 500 kcal/day)
- 5–9%
- Energy deficit → generalised fat mobilisation (not VAT-specific)
- None peptide-related
- Subcutaneous fat loss predominates. VAT reduction minimal without GH-mediated lipolysis